Cardiovascular Health

Certain laboratory tests indicate stronger predictions for hospital stay, suggesting pharmaceutical intervention could help reduce the length of cardiovascular-related hospital stay.

Food insecurity in rural communities can affect hypertension, but pharmacists can mitigate the impact by educating themselves on nutrition options for low-income individuals.

Snehal Bhatt discusess the need to individualize antiplatelet therapy decisions based on a comprehensive assessment of each patient's unique risk factors for thrombosis and bleeding.

The pumps can now be used to treat pediatric patients who have symptomatic acute decompensated heart failure and cardiogenic shock.

Rural patients face significant barriers to health care access and affordability that contribute to poor hypertension management.

Snehal Bhatt emphasizes the need for patient-specific risk assessment and a thoughtful approach to balancing aspirin's benefits and bleeding risks as new treatment options become available.

Glucagon-like peptide 1 (GLP1) receptor agonists were shown to be associated with a reduced risk of venous thromboembolism (VTE), while high dietary fiber intake was shown to enhance microbiome health, lower graft-versus-host disease (GVHD) severity, and improve overall survival following allogeneic hematopoietic cell transplantation.

Postural orthostatic tachycardia syndrome (POTS) diagnoses have greatly increased following the COVID-19 pandemic.

AI-enabled remote cardiac telemetry can help manage stress’s effects on high-risk populations.

In trials, blood pressure reductions were maintained over extended periods, suggesting that the drug could offer a sustained effect.

The approval is based on clinical studies that demonstrate the management of heart rate with minimal reductions to blood pressure.

Acoramidis is a novel, highly potent transthyretin stabilizer.

Recent studies suggest limited benefit post-myocardial infarction for patients with preserved heart function, prompting potential updates to treatment guidelines and reconsideration of long-term use.

Abelacimab is an investigational, selective, fully human monoclonal antibody.

Rachel Chandra, PharmD, MPH, FASHP, shares insight into the VALOR-QI program.

The encouraging results suggest this low-cost, scalable strategy should be considered for population-level outreach globally to improve flu vaccination rates.

Rachel Chandra, PharmD, MPH, FASHP shares methods for improving adherence to lipid lowering therapies discussed at the AHA 2024 Scientific Sessions.

Christian Ruff, MD, MPH shared the results of the AZALEA-TIMI 71 trial.

Leonard Egede, MD, MS, FACP discussed the association of historical redlining and contemporary structural racism on life expectancy.

Rebekah Walker, PhD raises awareness of the long-lasting health implications caused by historic redlining.

Value-based payment models are becoming increasingly common, leading clinicians to find novel ways to engage patients and improve disease control with the goal of reducing morbidity, mortality, and cost.

Within the Veterans Health Administration System, primary care pharmacists are embedded in primary care panels and work alongside primary care physicians and nurses to optimize medication management for patients.

Milind Desai, MD, MBA shares insight into the REMS program for patients with obstructive hypertrophic cardiomyopathy.

This is the first trial that tested the effect of any medication on major heart failure outcomes in patients with HFpEF and obesity, according to investigators.

The system, currently in early development in Japan, could minimize the need for blood tests, blood pressure cuffs, or expensive wearable devices.

The global temperature has risen by an average of 0.11° Fahrenheit per decade since 1850, or about 2 degrees in total.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP will be moderating a session about social determinants of health and heart failure.

Community pharmacists are playing an increasing role in sexual and reproductive health services and can provide that trustworthy information to patients.

The 2024 American Heart Association and American Stroke Association stroke prevention guidelines recommend glucagon-like peptide-1 receptor agonists to reduce the risk of stroke in individuals with diabetes and high cardiovascular risk.

These therapies represent an encouraging advancement in cardiovascular care.